1-methylcyclohexylcarbonyloxymethyl iodide | 126531-59-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-methylcyclohexylcarbonyloxymethyl iodide
• 英文别名: (1-methyl cyclohexan-1-yl)carbonyloxy methyl iodide；Iodomethyl 1-methylcyclohexane-1-carboxylate
• CAS: 126531-59-7
• 化学式: C₉H₁₅IO₂
• 分子量: 282.121
• InChiKey: SDZJHVPUXIQPKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  sodium(1S,5R,6S)-6-((1R)-1-hydroxyethyl)-2-(7-methanesulfonyl-5-methylimidazo[5,1-b]thiazol-2-yl)-1-methyl-1-carbapen-2-em-3-carboxylate 、 1-methylcyclohexylcarbonyloxymethyl iodide 生成 1-Methylcyclohexylcarbonyloxymethyl(1S,5R,6S)-6-((1R)-1-hydroxyethyl)-2-(7-methanesulfonyl-5-methylimidazo[5,1-b]thiazol-2-yl)-1-methyl-1-carbapen-2-em-3-carboxylate
  参考文献：
  名称：

  Carbapenem derivatives

  摘要：

  公开了一种新的碳青霉烯衍生物，其在碳青霉烯环的2位置具有取代的咪唑[5,1-b]噻唑基团，对产生β-内酰胺酶的细菌、耐甲氧西林金黄色葡萄球菌(MRSA)、抗假单胞菌属铜绿假单胞菌、肺炎链球菌(PRSP)、肠球菌和流感具有高的抗菌活性，并对DHP-1具有高稳定性。根据本发明，提供了一种由公式(I)表示的化合物，或其药理上可接受的盐，或其碳青霉烯环上3位置的酯。

  公开号：

  US06458780B1

文献信息

• Synthesis and Structure-activity Relationships of a Novel Oral Carbapenem, CS-834.
  作者：MASAO MIYAUCHI、ROKURO ENDO、MASAFUMI HISAOKA、HIROSHI YASUDA、ISAO KAWAMOTO

  DOI：10.7164/antibiotics.50.429

  日期：——

  We have studied an ester prodrug of a carbapenem to develop a potent orally active β-lactam antibiotic. A variety of 1β-methylcarbapenem derivatives have been synthesized. We have found that some derivatives having an amide group in the C-2 side chain show potent and well balanced antibacterial activities as well as high stability against dehydropeptidase-I. Oral absorption of derivatives has been optimized by modifying the C-3 ester promoiety. Pivaloyloxymethyl (1R, 5S, 6S)-6-[(R)-1-hydroxyethyl]-1-methyl-2-[(R)-5-oxopyrrolidin-3-ylthio]-1-carbapen-2-em-3-carboxylate, CS-834, has been selected as the most promising compound for further evaluation.

  我们研究了一种碳青霉烯酯类前药，旨在开发一种强效的口服活性β-内酰胺抗生素。合成了一系列1β-甲基碳青霉烯衍生物。我们发现，一些在C-2侧链中含有酰胺基团的衍生物显示出强大的且平衡的抗菌活性，并且对脱氨�酶-I具有高稳定性。通过修饰C-3酯的前体部分，优化了衍生物的口服吸收。Pivaloyloxymethyl (1R, 5S, 6S)-6-[(R)-1-羟基乙基]-1-甲基-2-[(R)-5-氧代吡咯烷-3-基硫]-1-碳青霉烯-2-em-3-羧酸酯，CS-834，已被选为最具前景的化合物进行进一步评估。
• Studies on penem and carbapenem. I. Syntheses and oral absorption of ester-type prodrugs of sodium (5R, 6S)-2-(2-fluoroethylthio)-6-((1R)-1-hydroxyethyl)penem-3-carboxylate.
  作者：Masao MIYAUCHI、Rokuro Endo、Katsuhiko Watanabe、Yukinori KAWAHARA、Masayuki IWATA、Isao KAWAMOTO

  DOI：10.1248/cpb.38.1587

  日期：——

  Acyloxyalkyl esters (2a-d), alkyloxycarbonyloxyalkyl esters (2e-g) and (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (2h) of (5R,6S)-2-(2-fluoroethylthio)-6-[(1R)-1-hydroxyethyl]penem-3- carboxylic acid (1) were synthesized. Enhanced oral absorption was observed in mice reflecting increased lipophilicity, compared with the parent 1 itself. Among them, the ester 2h showed a prolonged plasma level and

  （5R，6S）-2-（5）的烷氧基​​羰基氧基烷基酯（2a-d），烷氧基羰基氧基烷基酯（2e-g）和（5-甲基-2-氧代-1,3-二氧杂-4-基）甲基酯（2h）。合成了2-氟乙硫基）-6-[（（1R）-1-羟乙基] penem-3-羧酸（1）。与亲本1本身相比，在小鼠中观察到口服吸收增强，反映出亲脂性增加。其中，酯2h在大鼠的血药浓度-时间曲线（AUC）下显示血浆水平升高和面积增大。Penem 1的这些酯型前药在磷酸盐缓冲液（pH 6.86）中比头孢菌素稳定，后者容易通过异构化降解为δ2头孢菌素而降解。
• Novel carbapenem derivatives
  申请人：——

  公开号：US20030149016A1

  公开（公告）日：2003-08-07

  Disclosed is a novel carbapenem derivative having a substituted imidazo[5,1-b]thiazole group at the 2-position on the, carbapenem ring have high anti-microbial activities against &bgr;-lactamase producing bacteria, MRSA, resistant- Pseudomonas aeruginosa , PRSP, enterococci, and influenza, and high stabilities to DHP-1. According to the present invention, there is provided a compound represented by the formula (I), or a pharmacologically acceptable salt thereof or an ester at the 3-position on the carbapenem ring thereof: 1

  本发明公开了一种新型碳青霉烯衍生物，其在碳青霉烯环上的2位上具有取代咪唑[5,1-b]噻唑基团，对β-内酰胺酶产生的细菌、MRSA、耐药性假单胞菌、PRSP、肠球菌和流感病毒具有高抗菌活性，并对DHP-1具有高稳定性。根据本发明，提供了由式(I)表示的化合物，或其在碳青霉烯环上的3位处的药理学上可接受的盐或酯：1。
• Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy
  作者：Milan Dejmek、Andrea Brazdova、Tomáš Otava、Marketa Pimkova Polidarova、Martin Klíma、Miroslav Smola、Zdenek Vavrina、Miloš Buděšínský、Martin Dračínský、Radek Liboska、Evzen Boura、Gabriel Birkuš、Radim Nencka

  DOI：10.1016/j.ejmech.2023.115685

  日期：2023.11

  designed a novel class of CDNs containing vinylphosphonate based on a STING-affinity screening assay. In vitro, acyloxymethyl phosphate/phosphonate prodrugs of these vinylphosphonate CDNs were up to 1000-fold more potent than the clinical candidate ADU-S100. In vivo, the lead prodrug induced tumor-specific T cell priming and facilitated tumor regression in the 4T1 syngeneic mouse model of breast cancer

  环状二核苷酸 (CDN) 触发干扰素基因环 GMP-AMP 合酶刺激剂 (cGAS-STING) 途径，该途径在胞质 DNA 传感中发挥着关键作用，从而在针对感染、细胞损伤和癌症的免疫调节中发挥着关键作用。然而，CDN 的癌症免疫治疗试验显示免疫激活，但肿瘤并未完全消退。尽管如此，我们还是基于 STING 亲和力筛选试验设计了一类含有乙烯基膦酸酯的新型 CDN。在体外，这些乙烯基膦酸酯 CDN 的酰氧基甲基磷酸酯/膦酸酯前药的效力比临床候选 ADU-S100 强 1000 倍。在体内，先导前药诱导肿瘤特异性 T 细胞启动，并促进 4T1 同基因小鼠乳腺癌模型中的肿瘤消退。此外，我们还解析了与 STING 蛋白结合的配体的晶体结构。因此，我们的研究结果不仅验证了乙烯基膦酸酯 CDN 的治疗潜力，而且还为桥接先天免疫和适应性免疫的癌症免疫治疗药物开发开辟了机会。
• 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics
  申请人：Sankyo Company Limited

  公开号：EP0337637A1

  公开（公告）日：1989-10-18

  Compounds of formula (I): in which Ra is a group of formula (II): or a group of formula (III): (where one of R' is a bond to the remainder of the compound, one more of R is R2 and the others of R' are all hydrogen), R1 is hydrogen or methyl, R2 is hydrogen, optionally substituted alkyl, halogen, hydroxy, alkoxy, amino, alkanoylamino, alkanoyloxy, alkanoyl, carboxy, alkoxycarbonyl, cyano, -S(O)jR9 (where j is 0, 1 or 2 and R9 is alkyl), or -CONR6R7 (which is optionally subsituted carbamoyl or heterocyclyl-carbonyl), R2a is hydrogen, alkyl or alkanoyl, -NR3R4 is optionally substituted amino or heterocyclic, and -COORs is carboxy, -COO-, -COOMx (where M is a cation and x is the reciprocal of the valence of the cation M) or protected carboxy and, where -COOR5 is carboxy, -COOMx or protected carboxy, the compound of formula (I) also contains an anion; ℓ, m and n are independently 0, 1, 2 or 3, provided that (m + n) is an integer from 2 to 6; p is 0, 1 or 2; Y is a single bond, oxygen, sulphur or R8N< (wherein R8 is hydrogen, alkyl or alkanoyl) and pharmaceutically acceptable salts and esters thereof are potentially valuable antibiotics.

  式(I)化合物： 其中 Ra 是式 (II) 的基团 或式（III）的基团： (其中一个 R'是与化合物其余部分的键，另一个 R 是 R2，R'的其余部分均为氢），R1 是氢或甲基，R2 是氢、任选取代的烷基、卤素、羟基、烷氧基、氨基、烷酰氨基、烷酰氧基、烷酰基、羧基、烷氧羰基、氰基、-S(O)jR9（其中 j 是 0、1 或 2，R9 是烷基）、或-CONR6R7（其为任选取代的氨基甲酰基或杂环羰基），R2a 为氢、烷基或烷酰基，-NR3R4 为任选取代的氨基或杂环，-COORs 为羧基、-COO-、-COOMx（其中 M 是阳离子，x 是阳离子 M 的价的倒数）或受保护的羧基，且其中 -COOR5 是羧基、-COOMx 或受保护的羧基时，式 (I) 的化合物还包含一个阴离子；ℓ、m 和 n 独立地为 0、1、2 或 3，条件是（m + n）为 2 至 6 的整数；p 为 0、1 或 2；Y 为单键、氧、硫或 R8N<（其中 R8 为氢、烷基或烷酰基），其药学上可接受的盐和酯类是有潜在价值的抗生素。